#1 Clinical Trials Search in Europe

Cetrorelix

Cetrorelix is a medication that has been studied in various clinical trials for its potential benefits in reproductive health and benign prostatic hyperplasia (BPH). This article explores the use of Cetrorelix in different medical conditions, including infertility treatments, ovarian hyperstimulation syndrome (OHSS), and BPH. We’ll discuss its effectiveness, safety, and potential applications based on recent clinical trials.

Table of Contents

What is Cetrorelix?

Cetrorelix is a medication that belongs to a class of drugs known as gonadotropin-releasing hormone (GnRH) antagonists. It is also known by other names such as Cetrotide, D-20762, and AEZS-102[1]. This drug is primarily used in reproductive medicine and for treating certain hormonal conditions.

How Cetrorelix Works

Cetrorelix works by blocking the action of a hormone called GnRH in the body. GnRH is responsible for stimulating the production of other hormones like luteinizing hormone (LH) and follicle-stimulating hormone (FSH). By blocking GnRH, Cetrorelix can help control the levels of these hormones in the body, which is useful in various medical treatments[2].

Medical Conditions Treated with Cetrorelix

Cetrorelix is used to treat several medical conditions:

  • Infertility and Assisted Reproductive Technology (ART): Cetrorelix is commonly used during in vitro fertilization (IVF) procedures. It helps prevent premature ovulation, allowing doctors to better control the timing of egg retrieval[2][3].
  • Benign Prostatic Hyperplasia (BPH): This is a condition where the prostate gland enlarges, causing urinary symptoms in older men. Cetrorelix has been studied for its potential to improve symptoms of BPH[1].
  • Endometriosis: Cetrorelix has been investigated for treating symptoms of endometriosis, a condition where tissue similar to the lining of the uterus grows outside the uterus[4].
  • Ovarian Hyperstimulation Syndrome (OHSS): This is a potential complication of fertility treatments. Cetrorelix has been studied for its role in preventing and treating OHSS[5].

Administration and Dosage

Cetrorelix is typically administered in the following ways:

  • Subcutaneous injection: This means the medication is injected just under the skin. The common dose is 0.25 mg per day[2].
  • Intramuscular injection: In some cases, particularly for BPH treatment, Cetrorelix may be injected into the muscle, often in the buttocks[1].

The exact dosage and duration of treatment depend on the specific condition being treated and the individual patient’s response. Always follow your doctor’s instructions regarding dosage and administration.

Clinical Trials and Research

Cetrorelix has been the subject of numerous clinical trials investigating its effectiveness for various conditions:

  • Studies have compared different protocols for using Cetrorelix in IVF treatments, such as fixed versus flexible timing of administration[6].
  • Research has explored the use of Cetrorelix in treating BPH, with some studies showing promising results in improving urinary symptoms[7].
  • Trials have investigated the potential of Cetrorelix in managing endometriosis symptoms[4].
  • Some studies have looked at using Cetrorelix to prevent or treat ovarian hyperstimulation syndrome in women undergoing fertility treatments[5].

Potential Side Effects

Like all medications, Cetrorelix can cause side effects, although not everyone experiences them. Common side effects may include:

  • Injection site reactions (redness, swelling, or itching)
  • Nausea
  • Headache
  • Abdominal pain

More serious side effects are rare but can occur. Always inform your doctor if you experience any unusual symptoms while taking Cetrorelix[3].

Condition Cetrorelix Use Key Findings
Benign Prostatic Hyperplasia (BPH) Intramuscular injection Studied for safety and efficacy in reducing BPH symptoms
Infertility/IVF Subcutaneous injection Used to prevent premature LH surges during ovarian stimulation
Ovarian Hyperstimulation Syndrome (OHSS) Subcutaneous injection Investigated for potential in managing OHSS risk
Endometriosis Sustained-release formulation Explored for symptom relief in endometriosis patients

FAQ

  • What is Cetrorelix and how does it work? Cetrorelix is a gonadotropin-releasing hormone (GnRH) antagonist. It works by blocking the effects of GnRH, which helps control hormone levels in the body. This action makes it useful in various reproductive health treatments and other conditions affected by hormone levels.
  • In which medical conditions is Cetrorelix being studied? Cetrorelix is being studied in several medical conditions, including infertility treatments (such as in vitro fertilization), ovarian hyperstimulation syndrome (OHSS), endometriosis, and benign prostatic hyperplasia (BPH).
  • How is Cetrorelix administered? Cetrorelix is typically administered as a subcutaneous injection. The dosage and frequency can vary depending on the specific condition being treated and the protocol being followed. In some trials, it's given as a daily injection of 0.25 mg, while in others, it may be administered as a single dose or in different formulations.
  • What are some potential side effects of Cetrorelix? While specific side effects were not detailed in the provided trial information, GnRH antagonists like Cetrorelix may cause reactions at the injection site, headaches, nausea, and hormonal fluctuations. It's important to discuss potential side effects with a healthcare provider.
  • Is Cetrorelix effective in treating the conditions it's being studied for? The effectiveness of Cetrorelix varies depending on the condition being treated. In fertility treatments, it has shown promise in preventing premature LH surges. For BPH, studies are ongoing to determine its efficacy. More research is needed to fully understand its effectiveness in various conditions.

Ongoing Clinical Trials on Cetrorelix

  • Study of Fertility Preservation Using Tamoxifen, Follitropin Beta, Cetrorelix and Choriogonadotropin Alfa in Women with Breast Cancer Before Chemotherapy

    Recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France

  • Study on Infertility Treatment with Follitropin Alfa and Lutropin Alfa for Women Over 35 with Low Ovarian Response

    Recruiting

    1 1 1 1
    Investigated drugs:
    Spain

Glossary

  • Gonadotropin-releasing hormone (GnRH) antagonist: A type of medication that blocks the effects of GnRH, a hormone that plays a crucial role in regulating reproductive functions.
  • Benign Prostatic Hyperplasia (BPH): A non-cancerous enlargement of the prostate gland that can cause urinary symptoms in older men.
  • In Vitro Fertilization (IVF): A fertility treatment where eggs are fertilized by sperm outside the body in a laboratory setting.
  • Ovarian Hyperstimulation Syndrome (OHSS): A potential complication of fertility treatments where the ovaries become swollen and painful due to excessive stimulation.
  • Luteinizing Hormone (LH): A hormone produced by the pituitary gland that plays a key role in ovulation and testosterone production.
  • Controlled Ovarian Hyperstimulation (COH): A technique used in fertility treatments to stimulate the ovaries to produce multiple eggs.
  • Embryo Transfer: The process of placing an embryo into the uterus during fertility treatments.
  • Endometriosis: A condition where tissue similar to the lining of the uterus grows outside the uterus, often causing pain and fertility issues.

References

  1. https://clinicaltrials.gov/study/NCT00670306
  2. https://clinicaltrials.gov/study/NCT06023602
  3. https://clinicaltrials.gov/study/NCT05738382
  4. https://clinicaltrials.gov/study/NCT00244452
  5. https://clinicaltrials.gov/study/NCT02784457
  6. https://clinicaltrials.gov/study/NCT01005784
  7. https://clinicaltrials.gov/study/NCT00663858